Drug Information

Drug (ID: DG01803) and It's Reported Resistant Information

• Name: Chloroquinine phosphate
• Synonyms: Chloroquinine phosphate; TCMDC-123988; Tanakan; 1446-17-9; Chloroquine monophosphate; Araten phosphate; Chloroin; Delagil; Khingamin; Miniquine; Resochin; Rivoquine; Tanakene; Arolen; Aralen diphosphate; Gontochin phosphate; Chloroquin diphosphate; Ipsen 225; Chloroquine, phosphate; NSC14050; NSC-14050; 3377 RP; 4-N-(7-chloroquinolin-4-yl)-1-N,1-N-diethylpentane-1,4-diamine;phosphoric acid; SN 7,618; EGb761; Resochin diphosphate; Quinoline, diphosphate; CQ; CHEMBL1326; SCHEMBL40829; DTXSID10932343; Pharmakon1600-01500179; NSC756681; AKOS025310652; NSC-756681; 1,4-Pentanediamine, N4-(7-chloro-4-quinolinyl)-N1,N1-diethyl-, phosphate (1:1)-; Quinoline, 7-chloro-4-((4-(diethylamino)-1-methylbutyl)amino)-, phosphate (1:1); NCGC00180905-01; NCGC00180905-02; 941C583; WLN: T66 BNJ EMY1&3N2&2 IG &P2-O6; Q27268205; 1, N4-(7-chloro-4-quinolinyl)-N1,N1-diethyl-, phosphate (1:2); 7-Chloro-4-[(4'-diethylamino-1-methylbutyl)amino]quinoline diphosphate; Quinoline, 7-chloro-4-[(4-diethylamino-1-methylbutyl)amino]-, diphosphate (6CI); Phosphoric acid--N~4~-(7-chloroquinolin-4-yl)-N~1~,N~1~-diethylpentane-1,4-diamine (1/1)
• Indication:
  In total 1 Indication(s)
  Malaria [ICD-11: 1F40[; Approved; [1]
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug (1 diseases)
  Colon cancer [ICD-11: 2B90]; [1]
• Target: .; NOUNIPROTAC; [1]
• Formula: 8
• IsoSMILES: CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl.OP(=O)(O)O
• InChI: InChI=1S/C18H26ClN3.H3O4P/c1-4-22(5-2)12-6-7-14(3)21-17-10-11-20-18-13-15(19)8-9-16(17)18;1-5(2,3)4/h8-11,13-14H,4-7,12H2,1-3H3,(H,20,21);(H3,1,2,3,4)
• InChIKey: AEUAEICGCMSYCQ-UHFFFAOYSA-N
• PubChem CID: 83818
• DrugBank ID: DB01381

Type(s) of Resistant Mechanism of This Drug

  EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Colon cancer [ICD-11: 2B90]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: tumor protein p53 pathway corepressor 1 (TP53COR1) [1]

• Molecule Alteration: Up-regulation; Interaction
• Resistant Disease: Colon cancer [ICD-11: 2B90.1]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: HT29 Cells; Colon; Homo sapiens (Human); CVCL_A8EZ
• In Vitro Model: HCT116 cells; Colon; Homo sapiens (Human); CVCL_0291
• Experiment for Molecule Alteration: qRT-PCR; Western bloting analysis; Immunoprecipitation; Knockdown assay
• Mechanism Description: LincRNA-p21 Mediates the Anti-Cancer Effect of Ginkgo Biloba Extract EGb 761 by Stabilizing E-Cadherin Protein in Colon Cancer.

References

• Ref 1: lincRNA-p21 Mediates the Anti-Cancer Effect of Ginkgo Biloba Extract EGb 761 by Stabilizing E-Cadherin Protein in Colon CancerMed Sci Monit. 2018 Dec 30;24:9488-9496. doi: 10.12659/MSM.911924.